Accumulation of m

Area of Science:

• Neuroscience
• Pathology
• Genetics

Background:

• Alzheimer's disease (AD) research is limited by a lack of animal models that fully replicate its complex pathologies.
• Key AD hallmarks include extracellular beta-amyloid (Aβ) plaques, intracellular tau (MAPT) aggregation, neuroinflammation, and neurodegeneration.

Approach:

• Development of a double transgenic mouse model (APPNL-G-F/MAPTP301S) to simultaneously study major AD pathologies.
• Characterization of the model's pathological features at 6 months of age, including Aβ deposition, MAPT pathology, inflammation, and neurodegeneration.
• Investigation of the role of N6-methyladenosine (m6A) accumulation and its associated enzymes (METTL3, ALKBH5) in the model.

Key Points:

• The APPNL-G-F/MAPTP301S mouse model displays robust Aβ plaque accumulation, MAPT pathology, inflammation, and neurodegeneration by 6 months.
• Aβ pathology potentiates MAPT pathology, inflammation, and neurodegeneration, while MAPT pathology does not affect Aβ levels.
• Significant accumulation of N6-methyladenosine (m6A) is observed in neurons, astrocytes, and microglia, correlating with altered METTL3 and ALKBH5 enzyme levels.

Conclusions:

• The APPNL-G-F/MAPTP301S mouse serves as a comprehensive preclinical model for Alzheimer's disease.
• This model recapitulates critical AD pathologies and the recently identified m6A dysregulation, facilitating further investigation into AD pathogenesis and therapeutic strategies.